{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:06Z","timestamp":1791903306120,"version":"4.3.4"},"reference-count":21,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Classic Hodgkin lymphoma (cHL) associated with Epstein-Barr virus (EBV) positive status as well as nonnodular sclerosis (non-NS) histologic subtypes has demonstrated poorer outcomes compared with EBV\u2212 and NS tumors. We report a prespecified subset analysis of patients enrolled in the phase 3 SWOG S1826 trial to evaluate outcomes based on EBV status and histologic subtype in patients treated with N-AVD (nivolumab-AVD) or BV-AVD (brentuximab vedotin-AVD). In the phase 3 SWOG S1826 trial, patients with stage III to IV cHL were randomized to N-AVD or BV-AVD treatment. Of 970 eligible patients, 522 had known EBV status. N-AVD improved 3-year progression-free survival (PFS) in patients who were EBV+ (91% vs 70%; hazard ratio [HR], 0.30; P = .01) and EBV\u2212 (90% vs 84%; HR, 0.64; P = .09). Among 664 patients with slides available for histology review, 102 (15.4%) had non-NS histologic subtypes. N-AVD prolonged 3-year PFS in patients with non-NS histologic subtype (86% vs 63%; HR, 0.33; P = .006) and NS histologic subtype (93% vs 86%; HR, 0.53; P = .01). Non-NS histologic subtype was independently associated with inferior outcomes (HR, 2.54; P&amp;lt; .0001) after adjusting for treatment in the entire cohort. However, N-AVD treatment still had favorable PFS within this high-risk group. In addition, patients with EBV+ status or non-NS histologic subtype cHL treated with BV-AVD had significantly worse PFS (HR, 1.97; P = .03 for EBV and HR, 3.08; P&amp;lt; .0001 for histology). N-AVD substantially abrogated the historically poor prognosis associated with EBV+ status and non-NS histologic subtype in advanced-stage cHL. These results support N-AVD as a frontline standard of care, particularly in high-risk biologic subgroups. This trial was registered at www.clinicaltrials.gov as NCT03907488.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026021402","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:58:56Z","timestamp":1785369536000},"page":"6675-6682","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826)"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"first","affiliation":[{"name":"1Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"2Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"3City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamarija M.","family":"Perry","sequence":"additional","affiliation":[{"name":"4Department of Pathology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Kovach","sequence":"additional","affiliation":[{"name":"5Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Rutherford","sequence":"additional","affiliation":[{"name":"6Department of Medicine, New York University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Davison","sequence":"additional","affiliation":[{"name":"7Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-2002","authenticated-orcid":false,"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"9Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"6Department of Medicine, New York University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-6897","authenticated-orcid":false,"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[{"name":"11Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"12Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"13Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"2Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"14Wilmot Cancer Institute, University of Rochester Medicine, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Y.","family":"Song","sequence":"additional","affiliation":[{"name":"3City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"7","key":"2026101310414187600_bib1","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1182\/blood-2004-09-3759","article-title":"Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study","volume":"106","author":"Jarrett","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2026101310414187600_bib2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ajh.24184","article-title":"Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics","volume":"90","author":"Glimelius","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"2026101310414187600_bib3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2026101310414187600_bib4","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"Kuppers","year":"2012","journal-title":"J Clin Invest"},{"issue":"8","key":"2026101310414187600_bib5","doi-asserted-by":"crossref","first-page":"e1033","DOI":"10.1097\/MPH.0000000000002403","article-title":"Epstein-Barr virus in childhood and adolescent classic Hodgkin lymphoma in a French cohort of 301 patients","volume":"44","author":"Pereira","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"issue":"23","key":"2026101310414187600_bib6","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2008.20.5138","article-title":"Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients","volume":"27","author":"Diepstra","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026101310414187600_bib7","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"30","key":"2026101310414187600_bib8","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1200\/JCO.2005.02.6310","article-title":"Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study","volume":"23","author":"Keegan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026101310414187600_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ncponc1186","article-title":"Treatment of Hodgkin lymphoma: the past, present, and future","volume":"5","author":"Evens","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"18","key":"2026101310414187600_bib10","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"issue":"15","key":"2026101310414187600_bib11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"2026101310414187600_bib12","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017","edition":"Revised 4th ed"},{"issue":"35","key":"2026101310414187600_bib13","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026101310414187600_bib14","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026101310414187600_bib15","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2026101310414187600_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2026101310414187600_bib17","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","article-title":"Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials","volume":"9","author":"Kahn","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026101310414187600_bib18","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"2026101310414187600_bib19","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The advanced-stage Hodgkin Lymphoma International Prognostic Index: development and validation of a clinical prediction model from the HoLISTIC Consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10450","key":"2026101310414187600_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"2026101310414187600_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6675\/2592413\/blooda_adv-2026-021402-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6675\/2592413\/blooda_adv-2026-021402-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:41:50Z","timestamp":1791902510000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6675\/569968\/Impact-of-EBV-status-and-histology-on-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":21,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021402","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,29]]}}}